';
CLOSE
Authors Posts by Jason Snyder

Jason Snyder

307 POSTS 0 COMMENTS

0 1388

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is making available $4 million in grant funding for organizations to establish or expand substance use disorder (SUD) services, community outreach and education to Black, Indigenous, and People of Color (BIPOC) communities.

In 2020, overdose death rates increased 39 percent for black Pennsylvanians, compared to 2019. In 2021, black Pennsylvanians died from an overdose at a rate that was nearly two times higher than white Pennsylvanians.

Grants up to $400,000 each will be awarded for a 12-month period beginning July 1, 2023, through June 30, 2024. Funds can be applied toward a range of activities, including construction and building infrastructure, staffing, and evidence-based programming.

Eligible applicants include organizations that provide services, outreach, and/or education to BIPOC communities in any of the following areas:

  • Harm reduction;
  • Access to low-barrier medications for opioid use disorder and SUD treatment;
  • Recovery and peer supports; and
  • Reentry supports.

Funding for these grants is provided from the opioid settlement funding that the General Assembly appropriated to DDAP.

Download the Grant Initiative Funding Application.

0 1291

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) today announced the availability of more than $4 million in grant funding for the establishment of regional recovery hubs to enhance recovery supports and promote recovery within communities across Pennsylvania.

The nine regional recovery hubs throughout Pennsylvania will be designed to work to embed, expand, and promote a recovery-oriented system of care in each region using a hub and spoke model. Each regional “hub” will support community-driven services that will serve as spokes. Each hub will provide technical assistance and collaborate with a variety of community entities, sectors, and systems to enhance a recovery-supportive community and facilitate recovery support service delivery.

For more information, read the Grant Initiative Funding Application or visit DDAP’s Funding and Grants Process web page.

0 1076

The Pennsylvania Department of Drug and Alcohol Programs announced an open enrollment period at the end of 2022 for licensed substance use disorder (SUD) treatment providers in Pennsylvania to submit their information to be included in the Addiction Treatment Locator, Assessment, and Standards Platform (ATLAS). This open enrollment period has been extended through January 13, 2023.

Those who can take advantage of this extension include:

  1. Facilities already included in ATLAS. Providers already enrolled and needing to make changes to their profile information should contact Shatterproof directly.
  2. Facilities that have not submitted the treatment facility survey. Shatterproof will reach out directly to licensed SUD facilities that are not currently included on the tool. There is a streamlined submission process for those organizations with multiple facilities.

By completing the ATLAS survey during this open enrollment period, providers ensure that the information presented in their site’s profile on the ATLAS website is accurate. Providers also gain access to a customized portal that allows them to benchmark and compare their services against their peers. Contact Angad Buttar with questions or to have the treatment facility survey resent to your agency.

0 989

The Department of Drug and Alcohol Programs issued Information Bulletin 04-22 today. The purpose of the bulletin is to make Single County Authorities, substance use disorder (SUD) treatment providers, and other SUD-related organizations aware that they may be asked to serve on a death review team and that they may be asked to provide records as part of a death review team’s duties pursuant to Act 101 of 2022.

Read Information Bulletin 04-22.

0 3439

Act 111, which amends the Controlled Substance, Drug, Device and Cosmetic Act of 1972 to no longer define fentanyl test strips as drug paraphernalia, took effect Monday. Under the new law, people in Pennsylvania who buy or carry fentanyl testing strips will no longer face potential criminal charges for possession of drug paraphernalia.

According to the Centers for Disease Control and Prevention, fentanyl test strips (FTS) are a low-cost method of helping prevent drug overdoses and reducing harm. FTS are small strips of paper that can detect the presence of fentanyl in all different kinds of drugs (e.g., cocaine, methamphetamine, and heroin) and drug forms (pills, powder, and injectables).

0 7678

With the passage and signing into law of a federal omnibus appropriations bill last week, the requirement that healthcare providers possess a Drug Enforcement Administration (DEA) X-waiver to prescribe buprenorphine to treat opioid use disorder (OUD) has been eliminated. The move is intended to expand access to addiction treatment.

Named for the “x” that accompanies a narcotics prescribing license, DEA X-waivers have been required to prescribe buprenorphine, a Schedule III drug, as treatment for OUD. Applying for an X-waiver required providers to undergo additional training. The X‑waiver requirement had also limited the number of patients providers can treat. It was largely seen as a barrier preventing many practitioners from treating addiction.

Read the White House’s statement on elimination of the X-waiver.

0 1119

The Substance Abuse and Mental Health Services Administration (SAMHSA) is proposing to expand access to treatment for opioid use disorder (OUD) by making permanent medication flexibilities put in place during the COVID pandemic, including an increase in number of take-home doses of methadone and the use of telehealth in initiating buprenorphine at opioid treatment programs (OTPs).

In its Notice of Proposed Rulemaking to update 42 CFR Part 8, SAMHSA is proposing to improve access to OUD treatment through OTPs. The proposed changes reflect the widespread desire by many stakeholders for SAMHSA to provide greater autonomy to OTP practitioners, positively support recovery, and continue flexibilities that were extended at the start of the nation’s COVID-19 public health emergency. For example, in March and April 2020, SAMHSA published flexibilities for the provision of take-home doses of methadone and for the use of telehealth in initiating buprenorphine in OTPs. Patients deemed stable by physicians have been able to take home up to 28 days’ worth of methadone doses; other patients — again, so determined by their physicians — received up to a 14-day supply. A recent study showed that patients who received increased take-home doses after federal flexibilities were enacted during COVID-19 saw positive impacts on their recovery, including being more likely to remain in treatment and less likely to use illicit opioids.

Read the full announcement.

Prev1...111213...31Next Page 12 of 31
© 2021 - Rehabilitation & Community Providers Association